ARRY-382

Ligand id: 9108

Name: ARRY-382

Immunopharmacology Comments
ARRY-382 is predicted to inhibit tumour cell proliferation in CSF1R-overexpressing tumours, by inhibiting activity of tumour-associated macrophages (TAMs).